MicroRNA-33 and SIRT1 influence the coronary thrombus burden in hyperglycemic STEMI patients

Area of Science:

• Cardiovascular Medicine
• Molecular Biology
• Biochemistry

Background:

• Primary percutaneous coronary intervention (PPCI) is standard for ST-elevation myocardial infarction (STEMI).
• Hyperglycemia in STEMI patients is associated with significant mortality.
• The role of sirtuin 1 (SIRT1) and miR33 in hyperglycemic STEMI thrombi requires elucidation.

Purpose of the Study:

• Investigate the involvement of SIRT1 and miR33 in the pro-inflammatory and pro-coagulable state of coronary thrombi in hyperglycemic STEMI patients.
• Evaluate 1-year outcomes in hyperglycemic STEMI patients undergoing thrombus aspiration before PPCI.

Main Methods:

• Analysis of coronary thrombi size, miR33, reactive oxygen species, and pro-inflammatory/pro-coagulable markers in hyperglycemic STEMI patients.
• Assessment of endothelial SIRT1 expression in hyperglycemic thrombi.
• In vitro experiments on endothelial cells to determine the causal effect of SIRT1 modulation on hyperglycemia-induced miR33 expression.
• Correlation of SIRT1 expression with 1-year STEMI patient outcomes.

Main Results:

• Hyperglycemic STEMI thrombi were larger and showed increased miR33, reactive oxygen species, and pro-inflammatory/pro-coagulable markers.
• Endothelial SIRT1 expression was lower in hyperglycemic thrombi.
• In vitro studies confirmed SIRT1's causal role in regulating the pro-inflammatory/pro-coagulative state via hyperglycemia-induced miR33.
• Lower SIRT1 expression correlated with poorer STEMI outcomes.

Conclusions:

• The miR33/SIRT1 pathway is implicated in the heightened pro-inflammatory and pro-coagulable state of coronary thrombi in hyperglycemic STEMI.
• SIRT1 expression is a potential prognostic marker for outcomes in hyperglycemic STEMI patients.